Paul Moore
Chief Scientific Officer Zymeworks
Seminars
Tuesday 9th March 2027
Enhancing the Therapeutic Potential of Topoisomerase Inhibitor ADCs: From Concept to Clinical Validation
2:45 pm
- Learnings from 40+ years of ADC clinical development guiding ZD06519 Topo1i linker-payload design
- Presenting Phase 1 clinical proof of concept studies with ZW191, supporting a potential best-in-class Folate receptor alpha targeting ADC
- Applying ZD06519 to additional targets/ antibody formats to expand tumour type coverage and address target/tumour specific biology
